Screener
Wave Life Sciences WVE Contract Liabilities, Non-Current
Contract Liabilities, Non-Current at other companies
Other financials
Where this comes from
Reported directly by Wave Life Sciences in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The source filing: Wave Life Sciences’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 7:50 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-324949
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Current portion of operating lease liability | 3,508 | 8,361 |
| Total current liabilities | 50,815 | 95,065 |
| Long-term liabilities: | ||
| Deferred revenue, net of current portion | 13,904 | 7,798 |
| Operating lease liability, net of current portion | 40,082 | 9,405 |
| Total long-term liabilities | 53,986 | 17,203 |
| Total liabilities | $104,801 | $112,268 |
| Series A preferred shares, no par value; nil and 3,901,348 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | — | $7,874 |
Item 1. Financial Statements
FAQ
- What is Wave Life Sciences's contract liabilities, non-current?
- Wave Life Sciences (WVE) reported contract liabilities, non-current of $13.9M in Q2 2026.
- How has Wave Life Sciences's contract liabilities, non-current changed year-over-year?
- Wave Life Sciences's contract liabilities, non-current increased by 228.5% year-over-year, from $4.23M to $13.9M.
- What is the long-term trend for Wave Life Sciences's contract liabilities, non-current?
- Over 5 years (2020 to 2025), Wave Life Sciences's contract liabilities, non-current has grown at a -28.4% compound annual growth rate (CAGR), from $41.48M to $7.8M.
Ask your AI about Wave Life Sciences's contract liabilities, non-current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude